《大行報告》花旗下調中國中免(01880.HK)目標價至183元 評級「買入」
花旗發表報告指,中國中免(01880.HK)公布今年上半年初步業績,料收入按年升30%至358億元人民幣,純利按年跌2%至38億元人民幣,這意味著次季收入按年升39%至151億元人民幣,純利則按年升14%至15.6億元人民幣,又指公司收入復甦速度較預期慢。
該行指,中國中免毛利率已步入正軌,次季錄按季升3.67個百分點至30%,而公司最近將積分獎勵計劃更改為減少會員福利,亦表明了公司集中於平衡盈利能力和規模,料這會支撐下半年利潤率的持續復甦。
花旗將中國中免目標價由243元下調至183元,維持其評級為「買入」。(ca/w)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.